The Role of LINC02381 in Modulating Cisplatin Resistance  in Ovarian Cancer: A Bioinformatics Approach

Zeinab Karbalaei Pazoki; Bahram Mohammad Soltani; Mostafa Hosseini; Shiva Irani

doi:10.18502/ijaai.v24i5.19749

Zeinab Karbalaei Pazoki Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
Bahram Mohammad Soltani Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
Mostafa Hosseini Chemical Injuries Research Center, System Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
Shiva Irani Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran

DOI: https://doi.org/10.18502/ijaai.v24i5.19749

Keywords: Bioinformatics analysis; Chemoresistance; Cisplatin; LINC02381; Ovarian cancer

Abstract

Cisplatin resistance presents a significant challenge in cancer therapy, emphasizing the necessity for identifying new regulatory elements that influence drug response. Recent research has revealed the importance of long noncoding RNAs (lncRNAs) in chemotherapy resistance, with LINC02381 identified as a potential regulatory factor.

Through an in-depth bioinformatics analysis, we investigated the impact of LINC02381 on cisplatin resistance in ovarian cancer across various datasets. By conducting differential expression analysis, survival analysis, gene set enrichment analysis (GSEA), and constructing protein-protein interaction (PPI) networks, we identified key pathways associated with LINC02381 expression.

The results indicated that the altered expression of LINC02381 in patients treated with cisplatin was associated with reduced survival. Functional studies and correlation analyses further demonstrated that this LncRNA influences critical pathways and genes related to apoptosis, efflux, DNA repair, and EMT. Lastly, through an examination of its interactions with microRNA and protein networks, we identified LINC02381 as a ceRNA implicated in cisplatin resistance.

Our findings suggest that LINC02381 may influence cisplatin sensitivity in ovarian cancer and establish a basis for further experimental validation, including molecular assays or in vivo analyses, and suggest the potential therapeutic targeting of LINC02381 to combat chemoresistance.